Report: Tuesday, August 4, 2026, before the market opens
Conference call: 8:00 a.m. ET
Henry Schein enters the quarter with improving dental demand, early gross-margin progress, and a sizable cost and productivity program—but also with a substantially higher stock price and therefore a higher expectations bar.
A simple EPS beat may not be enough. The more important questions are:
| Metric | Q2 2026 consensus | Q2 2025 actual | Implied growth |
|---|---|---|---|
| Revenue | ~$3.37 billion | $3.24 billion | ~4% |
| Adjusted EPS | $1.23–$1.24 | $1.10 | ~12%–13% |
Published estimates vary slightly by provider, but generally cluster around $3.37 billion of revenue and $1.23–$1.24 of adjusted EPS. (benzinga.com)
Henry Schein currently guides to:
Dental was the strongest part of Q1. U.S. dental merchandise internal growth was 4.1%, equipment grew 3.4%, and management said the company was gaining market share. Global dental merchandise and equipment internal growth was 3.0% and 3.5%, respectively. Management subsequently said dental momentum continued through April and into May, supported by share gains and a more aggressive commercial posture.
The Q2 comparison is favorable. In Q2 2025:
That gives HSIC a reasonable path to solid reported growth and year-over-year margin improvement. The best result would combine positive volume, pricing, and market-share commentary—not merely growth against an easy comparison.
Key figures to watch:
Q1 non-GAAP operating margin increased 28 basis points to 7.53%, helped by distribution and technology gross margins, business mix, corporate brands, and early pricing initiatives. Management said savings should accelerate beginning in Q2 and become more significant in the second half. (investor.henryschein.com)
Investors should look for evidence in three areas:
The distinction between a year-end run rate and savings actually recognized in the Q2 income statement is important. Management can remain on track for $125 million while still reporting limited Q2 P&L benefit. The stock would likely respond better if management can quantify realized savings, not just future actions.
Global Specialty Products produced only 1.7% internal growth in Q1. Management attributed part of the weakness to transaction timing and predicted better growth during the rest of 2026.
The underlying picture is mixed:
A good Q2 would show internal growth moving clearly above Q1’s 1.7%, preferably without another meaningful decline in segment gross margin.
Global Technology grew 6.9% internally in Q1, supported by Dentrix Ascend and Dentally cloud adoption. The company had more than 13,000 cloud subscribers, up approximately 25% year over year, and was introducing additional AI-enabled clinical workflow capabilities.
Technology matters disproportionately because it offers:
Investors should watch whether internal growth remains in the mid- to high-single digits and whether management provides concrete adoption metrics for newer AI products.
Q1 U.S. Medical internal sales grew only 1.2%, reflecting weak demand for respiratory diagnostic tests after a light flu season. Management said the underlying business would have grown at a mid-single-digit rate excluding that category and later indicated those underlying trends continued into Q2.
Home Solutions and dialysis remain the principal positives. The complication is that Q2 2025 was relatively strong: U.S. Medical internal growth was 4.6%. (investor.henryschein.com)
Accordingly, a return to mid-single-digit Medical growth would be a meaningful positive rather than an easy comparison-driven rebound.
At the current Q2 consensus, first-half adjusted EPS would equal approximately:
That would leave $2.68–$2.82 of EPS required in the second half to achieve the existing $5.23–$5.37 guidance range. Henry Schein generated approximately $2.72 in the second half of 2025.
In other words, the existing guide requires roughly flat to low-single-digit second-half EPS growth, despite:
That could mean the outlook contains conservatism—but it may also reflect expected offsets from mix, inflation, freight, investment spending or limited organic growth.
A guidance raise is possible but not necessary for a constructive report. A reaffirmation accompanied by stronger internal-growth assumptions and detailed confidence in the $125 million run-rate target could still be well received. Conversely, a simple reaffirmation with vague or cautious second-half commentary may disappoint.
Q1 adjusted EPS rose 14.8%, but adjusted net income grew only 6.5%. Share repurchases were therefore an important component of per-share growth. Q1 EPS also included approximately $0.07 from a remeasurement gain related to the S.I.N. transaction.
For Q2, investors should prioritize:
HSIC repurchased $125 million of stock in Q1 and retained $655 million of authorization. Buybacks remain supportive, but the stronger investment case requires improvement in the underlying operation rather than financial engineering alone. (investor.henryschein.com)
On July 30, Henry Schein announced a flatter leadership structure, the integration of global supply chain with global distribution, and the planned transition of three long-tenured executives—including its COO and chief strategy officer—to advisory roles after October 30.
The changes fit CEO Fred Lowery’s stated objective of making Henry Schein simpler, faster and less siloed. They also introduce short-term execution and succession questions. Investors should listen for:
The announcement could ultimately be viewed as evidence that the new CEO is acting decisively, but management will need to demonstrate that the transition is controlled rather than disruptive. (marketbeat.com)
HSIC closed August 3 at approximately $86.53, up about 20% from the trading day before Q1 earnings and near its recent high. At that price, the shares trade around 16.3 times the midpoint of 2026 adjusted EPS guidance. (benzinga.com)
That is not an extreme valuation, but the rally means investors are already assigning some value to:
The near-term risk/reward therefore looks more dependent on margins and forward commentary than on a small revenue beat.
Given the stock’s recent appreciation, that result could produce only a muted positive reaction.
The most decision-useful figures and comments will be:
The setup is fundamentally constructive: dental trends improved into the quarter, Q2 comparisons are favorable, Medical and Specialty have identifiable recovery paths, and savings should begin contributing more visibly.
But with HSIC up roughly 20% since the last report, the burden of proof has shifted. The most bullish outcome is not simply $1.25 of EPS instead of $1.23—it is evidence that Henry Schein can sustain market-share gains while converting its value-creation program into recurring margin expansion.